GenSight Biologics SA (FR:SIGHT)
:SIGHT
Top Page
GenSight Biologics SA
(SIGHT)
Select Model
Select Model
Rating:45Neutral
Price Target:
€0.08
▼(-7.78% Downside)
Action:ReiteratedDate:03/28/26
The score is primarily held down by weak financial performance: collapsing revenue, persistent losses, ongoing cash burn, and a stressed balance sheet with negative equity. Technicals are more neutral (not overbought, with near-oversold signals), but they do not offset the high fundamental risk. Valuation is hard to justify given negative earnings and no stated dividend support.
Positive Factors
Focused gene-therapy pipeline
GenSight's specialization in gene therapies for severe retinal and neuro-ophthalmic diseases targets high unmet medical need and niche markets. That focused R&D strategy supports durable IP value, potential regulatory incentives, and long development timelines that can create lasting franchise value if clinical milestones are met.
Negative Factors
Revenue collapse in 2025
Revenue fell almost entirely in 2025, showing no commercial scale or stable sales base. This destroys internal funding capacity, raises execution risk for costly development programs, and forces reliance on external capital or partnerships to sustain operations and progress clinical assets.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused gene-therapy pipeline
GenSight's specialization in gene therapies for severe retinal and neuro-ophthalmic diseases targets high unmet medical need and niche markets. That focused R&D strategy supports durable IP value, potential regulatory incentives, and long development timelines that can create lasting franchise value if clinical milestones are met.
Read all positive factors
GenSight Biologics SA (SIGHT) vs. iShares MSCI France ETF (EWQ)
Market Cap
€20.72M
Dividend YieldN/A
Average Volume (3M)616.46K
Price to Earnings (P/E)―
Beta (1Y)0.64
Revenue Growth-92.35%
EPS Growth63.25%
CountryFR
Employees16
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.03
Shares Outstanding235,044,330
10 Day Avg. Volume718,774
30 Day Avg. Volume616,456
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-0.62
Price to Sales (P/S)15482.52
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.40Price Target Upside344.44% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.58
Revenue Forecast (FY)€2.75M
GenSight Biologics SA Business Overview & Revenue Model
Company Description
GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops...
How the Company Makes Money
null...
GenSight Biologics SA Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
12
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.00K | 2.63M | 1.27M | 2.58M | 5.28M |
| Gross Profit | 0.00 | 2.63M | 3.00M | 2.58M | 5.28M |
| EBITDA | -11.24M | -14.76M | -21.73M | -26.77M | -25.52M |
| Net Income | -12.04M | -14.00M | -26.22M | -27.62M | -28.62M |
Balance Sheet | |||||
| Total Assets | 8.26M | 10.76M | 9.13M | 25.94M | 56.65M |
| Cash, Cash Equivalents and Short-Term Investments | 2.42M | 2.46M | 2.13M | 10.61M | 44.29M |
| Total Debt | 12.86M | 19.11M | 23.54M | 12.65M | 12.57M |
| Total Liabilities | 33.20M | 37.68M | 39.83M | 41.22M | 40.66M |
| Stockholders Equity | -24.94M | -26.92M | -30.67M | -15.28M | 15.99M |
Cash Flow | |||||
| Free Cash Flow | 0.00 | -12.94M | -24.67M | -34.01M | -17.17M |
| Operating Cash Flow | -9.17M | -12.94M | -24.66M | -33.75M | -17.14M |
| Investing Cash Flow | 180.00K | 17.00K | 209.00K | 172.00K | -16.00K |
| Financing Cash Flow | 8.94M | 13.54M | 15.86M | 95.00K | 23.74M |
GenSight Biologics SA Technical Analysis
Positive
0.09
Price Trends
0.08
Positive
0.09
Negative
0.12
Negative
Market Momentum
<0.01
Positive
50.54
Neutral
51.95
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:SIGHT, the sentiment is Positive. The current price of 0.09 is above the 20-day moving average (MA) of 0.09, above the 50-day MA of 0.08, and below the 200-day MA of 0.12, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 50.54 is Neutral, neither overbought nor oversold. The STOCH value of 51.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:SIGHT.
GenSight Biologics SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | €127.52M | -24.25 | -85.59% | ― | -10.91% | -25.57% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | €213.65M | -3.69 | -634.16% | ― | 111.76% | -22.45% | |
45 Neutral | €20.72M | -1.29 | 51.23% | ― | -92.35% | 63.25% | |
44 Neutral | €223.34M | -7.03 | -30.75% | ― | 150.80% | 67.81% |
* Healthcare Sector Average
FR:SIGHT
GenSight Biologics SA
0.09
-0.15
-63.33%
FR:ALCOX
Nicox SA
0.43
0.19
80.25%
FR:TNG
Transgene
0.78
0.14
21.50%
FR:ALCLS
Cellectis SA
3.09
1.92
163.93%
FR:GNRO
GeNeuro SA
0.03
-0.04
-57.75%
FR:ABNX
ABIONYX Pharma SA
3.62
2.45
208.35%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.